Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Mental Health

Date Submitted: Dec 13, 2020
Date Accepted: Mar 2, 2021
Date Submitted to PubMed: Mar 12, 2021

The final, peer-reviewed published version of this preprint can be found here:

Feasibility and Initial Outcomes of a Group-Based Teletherapy Psychiatric Day Program for Adults With Serious Mental Illness: Open, Nonrandomized Trial in the Context of COVID-19

Puspitasari AJ, Heredia D, Coombes BJ, Geske JR, Gentry MT, Moore WR, Sawchuk CN, Schak KM

Feasibility and Initial Outcomes of a Group-Based Teletherapy Psychiatric Day Program for Adults With Serious Mental Illness: Open, Nonrandomized Trial in the Context of COVID-19

JMIR Ment Health 2021;8(3):e25542

DOI: 10.2196/25542

PMID: 33651706

PMCID: 7954114

Feasibility and Initial Outcomes of a Group-Based Teletherapy Psychiatric Day Program for Adults with Serious Mental Illness: An Open, Non-Randomized Trial in the Context of COVID-19

  • Ajeng J Puspitasari; 
  • Dagoberto Heredia; 
  • Brandon J Coombes; 
  • Jennifer R Geske; 
  • Melanie T Gentry; 
  • Wendy R Moore; 
  • Craig N Sawchuk; 
  • Kathryn M Schak

ABSTRACT

Background:

In the context of COVID-19, many behavioral health services transitioned to teletherapy to continue delivering care for patients with mental illness. Studies that evaluate the outcome.

Objective:

This single-arm, non-randomized pilot study aimed to assess the feasibility and initial patient-level outcomes of a psychiatric transitional day program that switched from an in-person to a video teletherapy group during COVID-19.

Methods:

Patients with transdiagnostic conditions who were at risk of psychiatric hospitalization were referred to the Adult Transitions Program (ATP) at a large academic medical center in the United States. ATP was a 3-week intensive outpatient program that implemented group teletherapy guided by cognitive and behavioral principles delivered daily for 3 hours per day. Feasibility was assessed via retention, attendance rate, and rate of securing aftercare appointments prior to ATP discharge. Patients completed standardized patient-reported outcome measures at admission and discharge to assess program effectiveness for improving quality of mental health, depression, anxiety, and suicide risk.

Results:

Patients (N = 76) started the program between March to August of 2020. Feasibility was established with 70 (92.1%) completing the program, mean attendance of 14.43 (SD = 1.22) days, and 71 (94.7%) had at least one behavioral health aftercare service scheduled prior to ATP discharge. All patient-level reported outcomes demonstrated significant improvement on depression (95% Cl: -3.6 to -6.2; Cohen’s d = 0.77; p < 0.0001), anxiety (95% Cl: -3.0 to -4.9; Cohen’s d = 0.74; p < 0.0001), overall suicide risk (95% Cl: -0.5 to-0.1; Cohen’s d = 0.41; p = 0.019), wish to live (95% Cl: 0.3 to 1.0; Cohen’s d = 0.39; p = 0.0005), wish to die (95% Cl: -0.2 to-1.4; Cohen’s d = 0.52; p = 0.011), and overall mental health (95% Cl: 1.5 to 4.5; Cohen’s d = 0.39; p = 0.0003) from admission to discharge.

Conclusions:

Rapid adoption and implementation of a group-based teletherapy day program for adults at risk of psychiatric hospitalization appeared to be feasible and effective. Patients demonstrated high completion and attendance rates and reported significant improvements on psychosocial outcomes. Larger trials should be conducted to further evaluate the efficacy and effectiveness of the program through randomized controlled trials.


 Citation

Please cite as:

Puspitasari AJ, Heredia D, Coombes BJ, Geske JR, Gentry MT, Moore WR, Sawchuk CN, Schak KM

Feasibility and Initial Outcomes of a Group-Based Teletherapy Psychiatric Day Program for Adults With Serious Mental Illness: Open, Nonrandomized Trial in the Context of COVID-19

JMIR Ment Health 2021;8(3):e25542

DOI: 10.2196/25542

PMID: 33651706

PMCID: 7954114

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.